<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ910610-0046</DOCNO><DOCID>910610-0046.</DOCID><HL>   Technology Brief -- Genetics Institute Inc.:   Ortho Pharmaceutical Joins   Patent Lawsuit in Europe</HL><DATE>06/10/91</DATE><SO>WALL STREET JOURNAL (J), PAGE B3</SO><CO>   AMGN GENI JNJ</CO><MS>CONSUMER NON-CYCLICAL (NCY)TECHNOLOGY (TEC)</MS><IN>DRUG MANUFACTURERS (DRG)MEDICAL AND BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)</IN><RE>CALIFORNIA (CA)EUROPE (EU)GERMANY (GE)MASSACHUSETTS (MA)NEW JERSEY (NJ)NORTH AMERICA (NME)PACIFIC RIM (PRM)UNITED STATES (US)WESTERN EUROPE (WEU)</RE><LP>   Genetics Institute Inc., Cambridge, Mass., said a courtbattle has been joined in Europe over rights to theanti-anemia drug erythropoietin, or EPO.   The company said Johnson andamp; Johnson's Ortho Pharmaceuticalunit, which has licensed rights to a version of the drugdeveloped by Amgen Inc., filed a patent infringement lawsuitin Germany against Boehringer Mannheim G.m.b.H., a Germancompany that has licensed European rights to GeneticsInstitute's version of EPO. The suit charges that Boehringeris infringing upon the EPO patent Ortho has licensed,Genetics Institute added.</LP><TEXT>   In March, Genetics Institute lost a drawn-out patentbattle to Amgen, based in Thousand Oaks, Calif., over U.S.rights to the drug, one of biotechnology's biggest-sellingproducts. Now, a similar fight looms in Europe. Both GeneticsInstitute and Amgen have been issued European patentscovering processes used in making the genetically engineereddrug. Genetics Institute said it expects to receiveadditional European patents on EPO and, with Boehringer, isevaluating its &quot;legal alternatives&quot; on enforcing its Europeanpatent claims.</TEXT></DOC>